Abstract
Purpose Surgeon and hospital related features such as surgeries volume can be associated with treatment choices and treatment outcomes. Accounting for these covariates with propensity score (PS) analysis can be challenging due to clustered nature of the data. Previous studies have not focused solely on the PS estimation strategy when treatment effects are estimated using random effects model(REM). We studied PS estimation for clustered data using REM compared with logistic regression.
Methods Six different PS estimation strategies were tested using simulations with variable cluster-level confounding intensity (odds ratio(OR)=1.01 to OR=2.5): i) logistic regression PS excluding cluster- level confounders; ii) logistic regression PS including cluster-level confounders; iii) same as ii) but including cross-level interactions; iv), v) and vi), similar to i), ii) and iii) respectively but using REM instead of logistic regression PS. Same analysis were tested in a randomised controlled trial emulation of partial vs total knee replacement surgery. Simulation metrics included bias and mean square error (MSE). For trial emulation, we compared observational vs trial-based treatment effect estimates.
Results In most simulated scenarios, logistic regression including cluster-level confounders gave more accurate estimates with the lowest bias and MSE. E.g. with 50 clusters x 200 individuals and confounding intensity OR=1.5, the relative bias= 10% and MSE= 0.003 for (i), compared to 21% and, 0.010 for (iv). In the Trial emulation, all 6 PS strategies gave similar treatment effect estimates.
Conclusions Logistic regression including patient and surgeon/hospital-level confounders appears to be the preferred strategy for PS estimation. Further investigation with more complex clustered structure is suggested.
Competing interests Prof. Prieto-Alhambra’s research group has received grant support from Amgen, Chesi-Taylor, Novartis, and UCB Biopharma. His department has received advisory or consultancy fees from Amgen, Astellas, AstraZeneca, Johnson, and Johnson, and UCB Biopharma and fees for speaker services from Amgen and UCB Biopharma. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organised by DPA’s department and open for external participants organized by his department outside submitted work.
Ethics Approval and Informed Consent This study was approved by the secretary of state, having considered the recommendation from the Confidentiality Advisory Group (CAG reference: 17/CAG/0174). Informed ethical approval was given on the use of pseudonymised patients data included in the study.
Competing Interest Statement
Prof. Prieto-Alhambra's research group has received grant support from Amgen, Chesi-Taylor, Novartis, and UCB Biopharma. His department has received advisory or consultancy fees from Amgen, Astellas, AstraZeneca, Johnson, and Johnson, and UCB Biopharma and fees for speaker services from Amgen and UCB Biopharma. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organised by DPA's department and open for external participants organized by his department outside submitted work.
Funding Statement
Prof. Prieto-Alhambra's research group has received grant support from Amgen, Chesi-Taylor, Novartis, and UCB Biopharma. His department has received advisory or consultancy fees from Amgen, Astellas, AstraZeneca, Johnson, and Johnson, and UCB Biopharma and fees for speaker services from Amgen and UCB Biopharma. Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organised by DPA's department and open for external participants organized by his department outside submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the secretary of state, having considered the recommendation from the Confidentiality Advisory Group (CAG reference: 17/CAG/0174). Informed ethical approval was given on the use of pseudonymised patients data included in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵^ Joint senior authors
Data Availability
All data produced in the present study are available upon reasonable request to the correspondence author Prof Daniel Prieto-Alhambra
Abbreviations
- PS
- propensity score;
- OR
- odd ratio;
- REM
- random effects model;
- MSE
- mean square error;
- UKR
- unicompartmental knee replacement;
- TKR
- total knee replacement;
- NJR
- UK National Joint Registry
